CLINICAL TRIALS PROFILE FOR IMR-687
✉ Email this page to a colleague
Clinical Trials for IMR-687
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02998450 ↗ | A Study of IMR-687 in Healthy Adult Volunteers | Completed | Quintiles, Inc. | Phase 1 | The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects. |
NCT02998450 ↗ | A Study of IMR-687 in Healthy Adult Volunteers | Completed | Imara, Inc. | Phase 1 | The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects. |
NCT03401112 ↗ | A Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia) | Completed | Imara, Inc. | Phase 2 | A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia). |
NCT04053803 ↗ | An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia | Enrolling by invitation | Imara, Inc. | Phase 2 | This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability. |
NCT04411082 ↗ | A Study of IMR-687 in Subjects With Beta Thalassemia | Recruiting | Imara, Inc. | Phase 2 | A Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for IMR-687
Condition Name
Clinical Trial Locations for IMR-687
Trials by Country
Clinical Trial Progress for IMR-687
Clinical Trial Phase
Clinical Trial Sponsors for IMR-687
Sponsor Name